2 unchanged sentences
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023.
−Removed: The term “disclosure controls and procedures,”
−Removed: as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.
+Added: The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.
Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.
−Removed: Management’s Report on Internal Control Over Financial Reporting
−Removed: Our management is responsible for establishing and maintaining adequate “internal control over financial reporting,”
−Removed: as defined in Rule 13a-15(f) under the Exchange Act.
+Added: Management’s Report on Internal Control Over Financial Reporting
+Added: Our management is responsible for establishing and maintaining adequate “internal control over financial reporting,” as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the criteria set forth in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on the assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2023.
−Removed: This Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting.
−Removed: Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management’s report in this Report because we are a “smaller reporting company.”
+Added: This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting.
+Added: Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management’s report in this Annual Report because we are a “smaller reporting company.”
Changes in Internal Controls Over Financial Reporting
−Removed: There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d- 15(d) of the Exchange Act that occurred during the year ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic.
−Removed: We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.
+Added: There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December 31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitation on Effectiveness of Controls
5 unchanged sentences
The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions;
−Removed: over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.
+Added: over time, controls may become inadequate because of changes in conditions, or because the degree of compliance with policies or procedures may deteriorate.
Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Other Information
−Removed: Item 9C.
+Added: Insider Trading Arrangements
+Added: During the quarter ended December 31, 2023, none of our directors or officers (as defined in Rule 16a - 1 under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or a “non-Rule 10b5 - 1 trading arrangement” (each as defined in Item 408 (a) and (c), respectively, of Regulation S-K).
Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
1 unchanged sentence
Directors, Executive Officers and Corporate Governance
−Removed: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2023 annual meeting of shareholders.
−Removed: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2022 fiscal year.
+Added: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2024 annual meeting of shareholders.
+Added: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2023 fiscal year.
Executive Compensation
−Removed: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2023 annual meeting of shareholders.
−Removed: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2022 fiscal year.
+Added: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2024 annual meeting of shareholders.
+Added: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2023 fiscal year.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
−Removed: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2023 annual meeting of shareholders.
−Removed: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2022 fiscal year.
+Added: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2024 annual meeting of shareholders.
+Added: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2023 fiscal year.
Certain Relationships and Related Transactions, and Director Independence
−Removed: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2023 annual meeting of shareholders.
−Removed: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2022 fiscal year.
+Added: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2024 annual meeting of shareholders.
+Added: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2023 fiscal year.
Principal Accounting Fees and Services
−Removed: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2023 annual meeting of shareholders.
−Removed: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2022 fiscal year.
+Added: The information required by this item is incorporated by reference to the Company’s definitive proxy statement relating to the 2024 annual meeting of shareholders.
+Added: The definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the 2023 fiscal year.
Financial Statement and Exhibits
−Removed: (a)     Financial Statement
+Added: (a) Financial Statement
Our financial statements and related notes thereto are listed and included in this Annual Report on Form 10-K beginning on page F-1.
−Removed: (b)     Exhibits
Incorporated by Reference
1 unchanged sentence
Filed Herewith
−Removed: Investment Shareholders Agreement with respect to Biotechnology Developments for Industry, S.L, and VLP The Vaccines Company, S.L.U.
−Removed: dated June 30, 2017
−Removed: January 14, 2019
−Removed: S ale and Purchase of Shares Agreement of Biotechnology Developments for Industry, S.L.
−Removed: dated July 26, 2021
−Removed: July 27, 2021
−Removed: Sale and Purchase of Shares Agreement of VLP The Vaccine Company, S.L.U.
−Removed: dated July 26, 2021
−Removed: July 27, 2021
−Removed: Amendment No.
−Removed: 1 dated July 26, 2021 to the Service Framework Agreement  
−Removed: dated June 30, 2017
−Removed: July 27, 2021
Restated Certificate of Incorporation dated November 1, 2004
4 unchanged sentences
January 14, 2019
−Removed: Description of Securities
−Removed: August 13, 2020
+Added: Description of Registered Securities
+Added: March 30, 2020
+Added: Senior Secured Convertible Promissory Note due March 8, 2027, dated March 8, 2024
+Added: March 11, 2024
Dyadic International, Inc.
4 unchanged sentences
August 12, 2021
−Removed: POST-EFFECTIVE AMENDMENT NO.
−Removed: 1 TO FORM S-8 for Dyadic International, Inc.
−Removed: 2006 Stock Option Plan, Dyadic International, Inc.
−Removed: 2011 Equity Incentive Plan, and Dyadic International, Inc.
+Added: Form of Stock Option Agreement Pursuant to the Dyadic International, Inc.
2021 Equity Incentive Plan
−Removed: August 12, 2021
Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc.
2021 Equity Incentive Plan
+Added: Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc.
+Added: 2011 Equity Incentive Plan
January 14, 2019
14 unchanged sentences
and Joseph Hazelton dated November 9, 2021
−Removed: November 9, 2021
+Added: November 9, 2021
Form of Director and Officer Indemnification Agreement
January 14, 2019
−Removed: Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc.
−Removed: and Quentin Partners Co.
−Removed: dated December 30, 2010 and Renewal of Lease dated June 8, 2018
−Removed: March 30, 2020
−Removed: Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc.
−Removed: and Quentin Partners Co.
−Removed: dated December 30, 2010 and Renewal of Lease dated August 29, 2022
−Removed: 10.12†#
+Added: Lease Agreement with Jupiter Harbour Office, LLC dated August 19, 2023
+Added: November 8, 2023
Pharma License Agreement with Danisco US, Inc.
1 unchanged sentence
January 14, 2019
−Removed: 10.13†#
Commission Contract with VTT Technical Research Centre of Finland Ltd dated September 2, 2016
January 14, 2019
−Removed: 10.13.1†#
Commission Contract with VTT Technical Research Centre of Finland Ltd dated June 28, 2019
−Removed: 10.14†#
−Removed: Research Services Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.
−Removed: dated June 30, 2017
−Removed: January 14, 2019
−Removed: 10.15†#
Service Framework Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.
dated June 30, 2017
−Removed: January 14, 2019
−Removed: 10.16†#
−Removed: Feasibility Study Agreement with Sanofi-Aventis Deutschland GmbH dated September 7, 2018
−Removed: January 14, 2019
−Removed: 10.17†#
+Added: November 8, 2023
+Added: Amendment No.
+Added: 1 dated July 26, 2021, to the Service Framework Agreement dated June 30, 2017
+Added: July 27, 2021
License Agreement with VTT Technical Research Centre of Finland Ltd dated July 17, 2017
January 14, 2019
−Removed: 10.18†#
−Removed: Joint Development Agreement
−Removed: 10.19†#
+Added: Joint Development Agreement with Leprino Foods Company, dated May 12, 2022
Research and Commercialization Collaboration Agreement with Serum Institute of India Pvt.
Ltd., dated May 7, 2019
−Removed: 10.20†#
Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated May 5, 2019
−Removed: 10.20.1†#
Amended and Restated Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated June 24, 2020
June 29, 2020
−Removed: 10.21†#
−Removed: Sub-License Agreement among Dyadic International (USA), Inc., Luina Bio Pty Ltd.
−Removed: and Novovet Pty Ltd, dated April 26, 2019
−Removed: 10.21.1†#
−Removed: Shareholders Agreement among Dyadic International (USA), Inc., JCL Biologics Pty Ltd and Novovet Pty Ltd, dated April 26, 2019
−Removed: Open Market Sale Agreement by and between the Company and Jefferies LLC, dated August 13, 2020
−Removed: August 13, 2020
Master Services Agreement and Work Order, between Dyadic International (USA), Inc.
and CR2O B.V., Dated May 28, 2021
−Removed: 10.24†#
−Removed: Research, License, and Collaboration Agreement with Janssen dated December 16, 2021
−Removed: December 16, 2021
−Removed: 10.25†#
Alphazyme Sale Agreement dated January 18, 2023
January 23, 2023
−Removed: Code of Ethics (1)
+Added: RUBIC License Agreement dated April 6, 2023
+Added: April 6, 2023
+Added: Inzyme Development and Exclusive License Agreement, effective September 18, 2023
+Added: September 19, 2023
+Added: Securities Purchase Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024
+Added: March 11, 2024
+Added: Registration Rights Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024
+Added: March 11, 2024
+Added: Security Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024
+Added: March 11, 2024
+Added: Subsidiary Guarantee Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024
+Added: March 11, 2024
Subsidiaries of the Registrant
−Removed: January 14, 2019
−Removed: Consent of Independent Registered Public Accounting Firm
−Removed: Certification of Chief Executive Officer of Dyadic Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Financial Officer of Dyadic Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Executive Officer of Dyadic Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Financial Officer of Dyadic Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: Consent of Independent Registered Public Accounting Firm - Crowe LLP
+Added: Consent of Independent Registered Public Accounting Firm - Mayer Hoffman McCann P.C.
+Added: Power of Attorney (included on signature page)
+Added: Certification of Chief Executive Officer of Dyadic International, Inc, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Chief Financial Officer of Dyadic International, Inc.
+Added: Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Chief Executive Officer of Dyadic International, Inc.
+Added: Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Chief Financial Officer of Dyadic International, Inc.
+Added: Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: Policy Related to Recovery of Erroneously Awarded Compensation
Inline XBRL Instance Document
5 unchanged sentences
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
−Removed: *    This filing excludes schedules and similar attachments pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule will be furnished supplementary to the SEC upon request;
−Removed: provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished.
−Removed: **   Identifies each management contract or compensatory plan or arrangement.
−Removed: †     Portions of the exhibits have been omitted pursuant to a request for confidential treatment.
−Removed: #     Previously filed with the SEC.
−Removed: (1)    The Company elect to satisfy Regulation S-K §229.406(c) by posting its Code of Ethics on its website at www.dyadic.com.
+Added: ** Identifies a management contract or compensatory plan or arrangement.
+Added: † Certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+Added: # Previously filed with the SEC.
+Added: Furnished herewith.
Form 10-K Summary
8 unchanged sentences
(Principal Financial Officer and Principal Accounting Officer)
−Removed: Pursuant to the requirements of Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
+Added: POWER OF ATTORNEY
+Added: KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark A.
+Added: Emalfarb and Ping W.
+Added: Rawson, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.
+Added: Pursuant to the requirements of Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
Chief Executive Officer, Director
4 unchanged sentences
(Principal Financial Officer and Principal Accounting Officer)
−Removed: /s/ Michael P.
+Added: /s/ Patrick Lucy
Chairman, Director
7 unchanged sentences
Buckland, Ph.D.
−Removed: /s/ Patrick Lucy
+Added: /s/ Michael P.
March 28, 2024
2 unchanged sentences
Report of Independent Registered Public Accounting Firm (PCAOB ID 173 )
+Added: Report of Independent Registered Public Accounting Firm (PCAOB ID 199) F-3
Consolidated Balance Sheets as of December 31, 2023 and 2022
Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022
−Removed: Consolidated Statements of Stockholders’
−Removed: Equity for the Years Ended December 31, 2022 and 2021
+Added: Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022
Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022
1 unchanged sentence
Report of Independent Registered Public Accounting Firm
−Removed: To the Board of Directors and
−Removed: Stockholders of Dyadic International, Inc.:
+Added: Shareholders and the Board of Directors of Dyadic International, Inc.
+Added: Jupiter, Florida
Opinion on the Financial Statements
−Removed: We have audited the accompanying consolidated balance sheets of Dyadic International, Inc.
−Removed: and Subsidiaries (“Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, stockholders’
−Removed: equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”).
−Removed: In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.
+Added: We have audited the accompanying consolidated balance sheet of Dyadic International, Inc.
+Added: (the "Company") as of December 31, 2023, the related consolidated statements of operations, stockholders’ equity, and cash flows for the year ended December 31, 2023, and the related notes (collectively referred to as the "financial statements").
+Added: In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
−Removed: These financial statements are the responsibility of the Company’s management.
−Removed: Our responsibility is to express an opinion on the Company’s financial statements based on our audits.
+Added: These financial statements are the responsibility of the Company's management.
+Added: Our responsibility is to express an opinion on the Company's financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
−Removed: We conducted our audits in accordance with the standards of the PCAOB.
+Added: We conducted our audit in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
−Removed: As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
+Added: As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.
Accordingly, we express no such opinion.
−Removed: Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
+Added: Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
−Removed: Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
−Removed: We believe that our audits provide a reasonable basis for our opinion.
+Added: Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
+Added: We believe that our audit provide a reasonable basis for our opinion.
Critical Audit Matters
2 unchanged sentences
We determined that there are no critical audit matters.
+Added: /s/ Crowe LLP
+Added: We have served as the Company's auditor since 2023.
+Added: Livingston, New Jersey
+Added: March 28, 2024
+Added: Report of Independent Registered Public Accounting Firm
+Added: To the Board of Directors and
+Added: Stockholders of Dyadic International, Inc.:
+Added: Opinion on the Financial Statements
+Added: We have audited the accompanying consolidated balance sheet of Dyadic International, Inc.
+Added: and Subsidiaries (“Company”) as of December 31, 2022, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the year ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”).
+Added: In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.
+Added: Basis for Opinion
+Added: These financial statements are the responsibility of the Company’s management.
+Added: Our responsibility is to express an opinion on the Company’s financial statements based on our audits.
+Added: We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S.
+Added: federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
+Added: We conducted our audits in accordance with the standards of the PCAOB.
+Added: Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
+Added: The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
+Added: As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
+Added: Accordingly, we express no such opinion.
+Added: Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
+Added: Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
+Added: Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
+Added: We believe that our audit provides a reasonable basis for our opinion.
/s/Mayer Hoffman McCann P.C.
−Removed: We have served as the Company’s auditor since 2008.
−Removed: Peterburg, Florida
+Added: We have served as the Company’s auditor from 2008 through 2023.
+Added: Petersburg, Florida
March 28, 2024
4 unchanged sentences
Cash and cash equivalents
−Removed: $ 5,794,272  
−Removed: $ 15,748,480  
+Added: $ 6,515,028 $ 5,794,272
Short-term investment securities
−Removed: 6,847,270  
−Removed: 4,511,780  
+Added: 748,290 6,847,270
Interest receivable
−Removed: 58,285  
−Removed: 94,375  
+Added: 10,083 58,285
Accounts receivable
−Removed: 330,001  
−Removed: 277,831  
+Added: 466,159 330,001
Prepaid expenses and other current assets
−Removed: 392,236  
−Removed: 375,830  
+Added: 327,775 392,236
Total current assets
−Removed: 13,422,064  
−Removed: 21,008,296  
+Added: 8,067,335 13,422,064
Non-current assets:
+Added: Operating lease right-of-use asset, net
Investment in Alphazyme
−Removed: 284,709  
−Removed: 284,709  
−Removed: $ 13,712,818  
−Removed: $ 21,299,122  
−Removed: Liabilities and stockholders’
+Added: $ 8,219,236 $ 13,712,818
+Added: Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
−Removed: $ 1,276,313  
−Removed: $ 1,547,953  
+Added: $ 656,445 $ 1,276,313
Accrued expenses
−Removed: 955,081  
−Removed: 709,560  
+Added: 1,057,164 955,081
Deferred research and development obligations
−Removed: 40,743  
−Removed: 151,147  
+Added: 490,113 40,743
Deferred license revenue, current portion
−Removed: 176,471  
−Removed: 147,059  
+Added: Operating lease liability, current portion
Total current liabilities
−Removed: 2,448,608  
−Removed: 2,555,719  
+Added: 2,251,781 2,448,608
Deferred license revenue, net of current portion
−Removed: 176,471  
−Removed: 352,941  
+Added: Operating lease liability, net of current portion
Total liabilities
−Removed: 2,625,079  
−Removed: 2,908,660  
+Added: 2,340,651 2,625,079
Commitments and contingencies (Note 5)
−Removed: Stockholders’
−Removed: Preferred stock, $ .0001 par value:
+Added: Stockholders’ equity:
+Added: Preferred stock, $.
+Added: 0001 par value:
Authorized shares - 5,000,000 ;
none issued and outstanding
−Removed: Common stock, $ .001 par value:
+Added: Common stock, $.
+Added: 001 par value:
Authorized shares - 100,000,000 ;
issued shares - 41,064,563 and 40,816,602 , outstanding shares - 28,811,061 and 28,563,100 as of December 31, 2023 and 2022, respectively
−Removed: 40,817  
−Removed: 40,483  
+Added: 41,065 40,817
Additional paid-in capital
−Removed: 103,458,697  
−Removed: 101,026,496  
+Added: 105,044,756 103,458,697
Treasury stock, shares held at cost - 12,253,502
−Removed: ( 18,929,915 )  
( 18,929,915 ) ( 18,929,915 )
Accumulated deficit
−Removed: ( 73,481,860 )  
( 80,277,321 ) ( 73,481,860 )
−Removed: Total stockholders’
−Removed: 11,087,739  
−Removed: 18,390,462  
−Removed: Total liabilities and stockholders’
−Removed: $ 13,712,818  
−Removed: $ 21,299,122  
+Added: Total stockholders’ equity
+Added: 5,878,585 11,087,739
+Added: Total liabilities and stockholders’ equity
+Added: $ 8,219,236 $ 13,712,818
The accompanying notes are an integral part of these audited consolidated financial statements.
4 unchanged sentences
Research and development revenue
+Added: $ 2,545,865 $ 2,683,244
License revenue
+Added: 352,941 247,059
Total revenue
+Added: 2,898,806 2,930,303
Costs and expenses:
Costs of research and development revenue
+Added: 1,975,849 2,123,193
Research and development
+Added: 3,297,266 4,501,365
General and administrative
+Added: 5,817,013 6,421,505
Foreign currency exchange loss
+Added: 38,417 49,918
Total costs and expenses
+Added: 11,128,545 13,095,981
Loss from operations
+Added: ( 8,229,739 ) ( 10,165,678 )
Other income:
Interest income
+Added: 416,686 180,420
+Added: Gain on sale of Alphazyme
Total other income
+Added: 1,434,278 430,420
+Added: $ ( 6,795,461 ) $ ( 9,735,258 )
Basic and diluted net loss per common share
+Added: $ ( 0.24 ) $ ( 0.34 )
Basic and diluted weighted-average common shares outstanding
+Added: 28,798,833 28,364,482
The accompanying notes are an integral part of these audited consolidated financial statements.
1 unchanged sentence
AND SUBSIDIARIES
−Removed: CONSOLIDATED STATEMENTS OF STOCKHOLDERS’
+Added: CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Treasury Stock
1 unchanged sentence
Balance at December 31, 2021
+Added: 40,482,659 $ 40,483 ( 12,253,502 ) $ ( 18,929,915 ) $ 101,026,496 $ ( 63,746,602 ) $ 18,390,462
Stock-based compensation expenses
+Added: — — — — 1,888,944 — 1,888,944
Issuance of common stock upon exercise of stock options
+Added: 333,943 334 — — 543,257 — 543,591
+Added: — — — — — ( 9,735,258 ) ( 9,735,258 )
Balance at December 31, 2022
+Added: 40,816,602 $ 40,817 ( 12,253,502 ) $ ( 18,929,915 ) $ 103,458,697 $ ( 73,481,860 ) $ 11,087,739
Stock-based compensation expenses
−Removed: Issuance of common stock upon exercise of stock options
+Added: — — — — 1,244,121 — 1,244,121
+Added: Issuance of common stock upon vesting of restricted stock units
+Added: 247,961 248 — — 341,938 — 342,186
+Added: — — — — — ( 6,795,461 ) ( 6,795,461 )
Balance at December 31, 2023
+Added: 41,064,563 $ 41,065 ( 12,253,502 ) $ ( 18,929,915 ) $ 105,044,756 $ ( 80,277,321 ) $ 5,878,585
The accompanying notes are an integral part of these audited consolidated financial statements.
4 unchanged sentences
Cash flows from operating activities
+Added: $ ( 6,795,461 ) $ ( 9,735,258 )
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
+Added: 1,244,121 1,888,944
Amortization of held-to-maturity securities, net
−Removed: Gain on investment in BDI
+Added: ( 53,032 ) 33,790
+Added: Gain on investment in Alphazyme
+Added: ( 1,017,592 ) —
Foreign currency exchange loss
+Added: 38,418 49,918
Changes in operating assets and liabilities:
+Added: Operating lease assets and liabilities, net
Interest receivable
+Added: 48,202 36,090
Accounts receivable
+Added: ( 141,332 ) ( 83,265 )
Prepaid expenses and other current assets
+Added: 64,902 ( 13,925 )
Accounts payable
+Added: ( 651,168 ) ( 248,128 )
Accrued expenses
+Added: 444,269 245,521
Deferred license revenue
+Added: ( 352,942 ) ( 147,058 )
Deferred research and development obligations
+Added: 449,370 ( 110,404 )
Net cash used in operating activities
+Added: ( 6,726,755 ) ( 8,083,775 )
Cash flows from investing activities
Purchases of held-to-maturity investment securities
+Added: ( 2,995,988 ) ( 9,869,280 )
Proceeds from maturities of investment securities
−Removed: Proceeds from the sale of investment in BDI
−Removed: Net cash (used in) provided by investing activities
+Added: 9,148,000 7,500,000
+Added: Proceeds from the sale of investment in Alphazyme
+Added: Net cash provided by (used in) investing activities
+Added: 7,449,896 ( 2,369,280 )
Cash flows from financing activities
2 unchanged sentences
Effect of exchange rate changes on cash
+Added: ( 2,385 ) ( 44,744 )
Net decrease in cash and cash equivalents
+Added: 720,756 ( 9,954,208 )
Cash and cash equivalents at beginning of period
+Added: 5,794,272 15,748,480
Cash and cash equivalents at end of period
+Added: $ 6,515,028 $ 5,794,272
+Added: Supplemental cash flow information
+Added: Vesting of restricted stock units
+Added: $ 342,186 $ —
+Added: Right-of-use asset obtained in exchange for lease obligations
+Added: $ 156,983 $ —
The accompanying notes are an integral part of these audited consolidated financial statements.
Notes to Consolidated Financial Statements
−Removed:      Organization and Summary of Significant Accounting Policies
+Added: Organization and Summary of Significant Accounting Policies
Description of Business
Dyadic International, Inc.
−Removed: (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes several third -party consultants and research organizations to carry out the Company’s activities.
−Removed: Over the past two plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications.
+Added: (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes third -party consultants and research organizations to carry out the Company’s activities.
+Added: Over the past two plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa BioenergySA, BASF SE, Codexis, Inc.
+Added: and others, for use in industrial (non-pharmaceutical) applications.
This technology is based on the Thermothelomyces heterothallica (formerly known as Myceliophthora thermophila ) fungus, which the Company named C1.
−Removed: On December 31, 2015, the Company sold its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE:
−Removed: DD) (the “DuPont Transaction”).
−Removed: As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 -cell protein production platform for use in all human and animal pharmaceutical applications, and currently the Company has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions) for use in all human and animal pharmaceutical applications.
−Removed: Danisco retained certain rights to utilize the C1 -cell protein production platform in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization.
−Removed: In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.
−Removed: After the DuPont Transaction, the Company has been focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health and for other biologic products for use in non-pharmaceutical applications.
−Removed: The C1 -cell protein production platform is a robust and versatile thermophilic filamentous fungal expression system for the development and production of biologic products including enzymes and other proteins for human and animal health.
−Removed: Some examples of human and animal vaccines and drugs which have the potential to be produced from C1 -cells are protein antigens, ferritin nanoparticles, virus-like particles (“VLPs”), monoclonal antibodies (“mAbs”), Bi/Tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, as well as other therapeutic enzymes and proteins.
+Added: Subsequent to the Company selling its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE:
+Added: DD) (the “DuPont Transaction”) on December 31, 2015, the Company has been focused on building the C1 -cell protein production platform for the development and production of biologic products including enzymes and other proteins for human and animal health.
+Added: Some examples of human and animal vaccines and drugs which have the potential to be produced from C1 -cells are protein antigens, ferritin nanoparticles, virus-like particles (“VLPs”), monoclonal antibodies (“mAbs”), Bi/Tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, as well as other therapeutic enzymes and proteins.
The Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies which are designed to leverage its C1 -cell protein production platform to develop innovative vaccines and drugs, biosimilars and/or biobetters.
−Removed: The Company also developed the Dapibus™
−Removed: thermophilic filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
+Added: The Company also developed the Dapibus™ thermophilic filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
Liquidity and Capital Resources
−Removed: We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flows to provide the working capital needs for our operations.
−Removed: We believe that our existing cash position and investments in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve ( 12 ) months. However, in the event our financing needs are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and/or other means to meet our financing requirements.
−Removed: The Company has self-funded the development and cGMP manufacturing costs of its proprietary COVID- 19 vaccine candidate, DYAI- 100, and in February 2023 completed the dosing of its related Phase 1 clinical trial to demonstrate the safety in humans of a protein produced from the C1 -cell protein production platform. We do not expect that significant amounts of additional capital will be needed to support the continued development, manufacturing and testing of DYAI- 100 in 2023 and beyond. 
−Removed: In January 2023, the Company received cash payment of approximately $ 1.27  million from the sale of its equity interest in Alphazyme, LLC. 
−Removed: See Note 8 Subsequent Events for details.
−Removed: Summary of Significant Accounting Policies
+Added: The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its microbial platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its third -party collaborators and licensees.
+Added: The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval and subsequent revenue generation or through the sublicensing of the Company’s technologies and products, to raise capital to finance these developmental efforts.
+Added: For the year ended December 31, 2023, the Company received $ 1.3 million from the sale of its equity interest in Alphazyme, LLC, and $ 600,000 upfront payment from a product development and licensing agreement.
+Added: On March 8, 2024, the Company sold and issued an aggregate principal amount of $ 6.0 million of its 8.0 % Senior Secured Convertible Promissory Notes due March 8, 2027 ( the “Convertible Notes”) in a private placement in reliance on the exemption from registration provided by Section 4 (a)( 2 ) of the Securities Act of 1933, as amended (the “Securities Act”).
+Added: The purchasers of the Convertible Notes include immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company’s outstanding common stock, (collectively, the “Purchasers”).
+Added: The Convertible Notes will be senior, secured obligations of Dyadic and its affiliates, and interest will be payable quarterly in cash on the principal amount equal to 8 % per annum.
+Added: The Convertible Notes will mature on March 8, 2027 ( the “Maturity Date”), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes.
+Added: The Convertible Notes can be converted into shares of Dyadic’s Class A common stock (the “Common Stock”), at the option of the holders of the Convertible Notes (the “Noteholders”) at any time prior to the Maturity Date.
+Added: The conversion price is $ 1.79 per share of the Common Stock, which is equal to 125 % of the trailing 30 -day VWAP of the Common Stock ending on the trading day immediately preceding the date of the securities purchase agreement.
+Added: This private placement funding strengthened our financial position, and it will support our new-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications.
+Added: The Company has received successful top-line results for the Phase 1 clinical trial of DYAI- 100, and we do not plan to continue Phase 2/3 clinical trials unless third -party funding is secured.
+Added: The Company expects its existing cash and cash equivalents and cash raised from the Convertible Notes, investments in debt securities, and operating cash flows will be sufficient to meet its operational, business, and other liquidity requirements for at least the next
+Added: 12 ) months from the date of issuance of the financial statements contained in this Form
+Added: However, the Company has based this estimate on assumptions that
+Added: may prove to be wrong, and its operating plan
+Added: may change as a result of many factors currently unknown to it.
+Added: In the event our financing needs are
+Added: not able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are
+Added: not limited to, future public or private equity offerings, collaboration agreements, and/or other means.
+Added: Any amounts raised
+Added: may be used for the further development and commercialization of product candidates, and for other working capital purposes.
+Added: no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders.
Basis of Presentation
1 unchanged sentence
Dyadic consolidates entities in which we have a controlling financial interest.
−Removed: We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights. All significant intra-entity transactions and balances have been eliminated in consolidation.
+Added: We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights.
+Added: All significant intra-entity transactions and balances have been eliminated in consolidation.
These consolidated financial statements have been prepared in conformity with U.S.
−Removed: generally accepted accounting principles (“GAAP”).
−Removed: The Company conducts business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made.
+Added: generally accepted accounting principles (“GAAP”).
+Added: The Company conducts business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made.
Management evaluates performance and allocates resources based on the Company as a whole.
1 unchanged sentence
The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period.
+Added: Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes.
+Added: The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances.
+Added: On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.
Actual results may differ from these estimates under different assumptions or conditions.
1 unchanged sentence
Concentrations and Credit Risk
−Removed: The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable.
−Removed: At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency.
+Added: The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable.
+Added: At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency.
The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
−Removed: For each of the years ended December 31, 2022 and 2021 , the Company’s revenue was generated from 
−Removed: fourteen  customers.
−Removed: December 31, 2022 and 2021 , the Company’s accounts receivable was from 
−Removed: six and eight  customers, respectively.
−Removed: The loss of business from one or a combination of the Company’s customers could adversely affect its operations.
+Added: For the years ended December 31, 2023 and 2022 , the Company’s revenue was generated from sixteen and fourteen customers, respectively.
+Added: As of December 31, 2023 and 2022 , the Company’s accounts receivable was from thirteen and six customers, respectively.
+Added: Significant customers are those that account for greater than 10% of the Company’s revenues.
+Added: For the years ended December 31, 2023 and 2022 , two and three signifi cant customers accounted for approximately $ 1,150,000 or 45.2 % an d $ 1,811,000 or 67.5 % of r esearch and development revenue, respectively.
+Added: The loss of business from one or a combination of the Company’s customers could adversely affect its operations.
The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States.
−Removed: For the years ended December 31, 2022 and 2021 , the Company had 
−Removed: six  and eight  customers outside of the United Sates (i.e.
−Removed: European and Asian customers) that accounted for approximately $ 586,000  or 
−Removed: 21.8 % and $ 1,716,000  or 
−Removed: 71.3 % of total revenue, respectively. As of 
−Removed: December 31, 2022 and 2021 , the Company had four  and four customers outside of the United Sates (i.e.
−Removed: European and Asian customers) that accounted for approximately $ 91,000  or 
−Removed: 27.4 % and $ 157,000  or 56.4 % of accounts receivable, respectively.
−Removed: The Company uses several contract research organizations (“CROs”) to conduct its research projects and manage its clinical trial.
−Removed: For the years ended December 31, 2022 and 2021 , 
−Removed: three CROs accounted for approximately $ 5,575,000  or 
−Removed: 97.9 % and $ 9,061,000  or 
−Removed: 95.1 % of total research services we purchased, respectively.
−Removed: December 31, 2022 , three  CROs accounted for approximately $ 1,018,000  or 79.7 % of accounts payable.
−Removed: December 31, 2021 , two  CROs accounted for approximately $ 1,312,000  or 84.8 % of accounts payable.
−Removed: The loss of business from any CRO or a combination of the Company’s CROs could adversely affect its operations.
+Added: For the years ended December 31, 2023 and 2022 , the Company had six customers outside of the United Sates (i.e.
+Added: European and Asian customers) that accounted for approximately $ 537,000 or 21.1 % and $ 586,000 or 21.8 % of total revenue, respectively.
+Added: As of December 31, 2023 and 2022 , the Company had six and four customers outside of the United Sates (i.e.
+Added: European and Asian customers) that accounted for approximately $ 213,000 or 45.6 % and $ 91,000 or 27.4 % of accounts receivable, respectively.
+Added: The Company uses contract research organizations (“CROs”) to conduct its research projects and manage its clinical trial.
+Added: For each of the years ended December 31, 2023 and 2022 , three CROs accounted for approximately $4,644,0 00 or 96.0 % and $ 5,575,000 or 97.9 % of total research services we purchased, respectively.
+Added: As of December 31, 2023 , three CROs accounted for approximately $ 620,000 or 94.4 % of a ccounts payable.
+Added: As of December 31, 2022 , three CROs accounted for approximately $ 1,018,000 or 79.7 % of accounts payable.
+Added: The loss of business from any CRO or a combination of the Company’s CROs could adversely affect its operations.
Cash and Cash Equivalents
1 unchanged sentence
Investment Securities
+Added: The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield.
The Company invests excess cash balances in short-term and long-term investment grade securities.
Short-term investment securities mature within twelve ( 12 ) months or less, and long-term investment securities mature over twelve ( 12 ) months from the applicable reporting date.
−Removed: Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date.
−Removed: The Company’s investments in debt securities have been classified and accounted for as held-to-maturity.
+Added: Management determines the appropriate classification of each investment at the time of purchase and reevaluates the classifications at each balance sheet date.
+Added: The Company classifies its investments in debt securities as held-to-maturity.
Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity.
−Removed: Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts.
+Added: Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts.
Premiums and discounts are amortized over the life of the related held-to-maturity security.
When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow.
−Removed: Other-than-temporary impairment charges, if incurred, will be included in other income (expense).
+Added: When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis.
+Added: The Company measures expected credit losses on held to maturity debt securities on an individual security basis.
+Added: The estimate of expected credit losses considers historical credit information from external sources.
+Added: The impairment of the investment that is related to the credit loss, if any, is expensed in the period in which the event or change occurred.
As of December 31, 2023 and 2022 , all of our money market funds were invested in U.S.
5 unchanged sentences
Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.
−Removed: Outstanding account balances are reviewed individually for collectability.
−Removed: The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable.
−Removed: Substantially all our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve ( 12 ) months.
−Removed: There was no allowance for doubtful accounts as of 
−Removed: December 31, 2022 and 2021 .
+Added: Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company’s evaluation of collectability and potential credit losses.
+Added: Management assesses the collectability of its accounts receivable using the specific identification of account balances and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company’s evaluation of current and expected future economic conditions and changes in our customer collection trends.
+Added: If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected.
+Added: Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote.
+Added: Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve ( 12 ) months.
+Added: Management determined that no allowance for credit losses was required as of December 31, 2023 and 2022 .
Accounts receivable consist of the following:
Billed receivable
−Removed: $ 115,469  
−Removed: $ 101,175  
+Added: $ 410,617 $ 115,469
Unbilled receivable
−Removed: 214,532  
−Removed: 176,656  
−Removed: $ 330,001  
−Removed: $ 277,831  
+Added: 55,542 214,532
+Added: $ 466,159 $ 330,001
Prepaid Expenses and Other Current Assets
1 unchanged sentence
Prepaid insurance
−Removed: $ 265,429  
−Removed: $ 326,712  
+Added: $ 209,888 $ 265,429
Prepaid expenses - various
−Removed: 124,273  
−Removed: 45,839  
+Added: 117,887 124,273
Prepaid taxes
−Removed: $ 392,236  
−Removed: $ 375,830  
+Added: $ 327,775 $ 392,236
Accounts Payable
1 unchanged sentence
Research and development expenses
−Removed: $ 1,067,958  
−Removed: $ 1,363,889  
Legal expenses
−Removed: 56,514  
−Removed: 27,675  
−Removed: 151,841  
−Removed: 156,389  
−Removed: $ 1,276,313  
−Removed: $ 1,547,953  
+Added: 79,052 151,841
+Added: $ 656,445 $ 1,276,313
Accrued Expenses
1 unchanged sentence
Employee wages and benefits
−Removed: $ 580,264  
−Removed: $ 405,758  
+Added: $ 561,720 $ 580,264
Research and development expenses
−Removed: 343,457  
−Removed: 194,250  
−Removed: 31,360  
−Removed: 109,552  
−Removed: $ 955,081  
−Removed: $ 709,560  
+Added: 274,080 343,457
+Added: Legal expenses
+Added: 11,360 31,360
+Added: $ 1,057,164 $ 955,081
Revenue Recognition
−Removed: The Company has no pharmaceutical products approved for sale at this point.
−Removed: All of our revenue to date has been research revenue from third -party collaborations and government grants, as well as revenue from sublicensing agreements and collaborative arrangements, which may include upfront payments, options to obtain a license, payment for research and development services, milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).
+Added: The Company has no products approved for sale.
+Added: All our revenue to date has been research revenue from third -party collaborations and government grants, as well as revenue from sublicensing agreements and collaborative arrangements, which may include upfront payments, options to obtain a license, payment for research and development services, milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest).
Revenue related to research collaborations and agreements:
−Removed: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5 -step process outlined in ASC Topic 606 (“Topic 606”
+Added: The Company typically performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5 -step process outlined in ASC Topic 606 (“Topic 606” ):
(i) identify the contract(s) with a customer;
4 unchanged sentences
We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive.
−Removed: Depending on how the performance obligation under our license and collaboration agreements is satisfied, we elected to recognize the revenue either at a point in time or over time by using the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. 
−Removed: Under the input method, revenue will be recognized based on the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation.
+Added: Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.
+Added: Under the input method, revenue will be recognized based on the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation.
The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer.
1 unchanged sentence
These costs consist primarily of full-time equivalent effort and third -party contract costs.
−Removed: Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. 
−Removed: A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations.
+Added: Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.
+Added: A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations.
In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates.
−Removed: The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated.
−Removed: A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. 
+Added: The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated.
+Added: A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.
Revenue related to grants:
−Removed: The Company may receive grants from governments, agencies, and other private and not -for-profit organizations.
−Removed: These grants are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID- 19 that the Company is pursuing with certain collaborators.
−Removed: However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV- 2 vaccines and/or antibodies candidates. 
+Added: The Company may receive grants from governments, agencies, and other private and not -for-profit organizations.
+Added: These grants are intended to be used to partially or fully fund the Company’s research collaborations .
+Added: However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV- 2 vaccines and/or antibodies candidates.
Revenue related to sublicensing agreements:
−Removed: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.
+Added: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license.
Customer options:
−Removed: If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate if such options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement. 
+Added: If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate if such options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement.
Milestone payments:
At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price.
−Removed: If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.
−Removed: To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements. 
−Removed: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
−Removed: To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements. 
+Added: If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties.
+Added: To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.
+Added: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied).
+Added: To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.
We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized.
When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate.
−Removed: If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. 
−Removed: We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed. 
+Added: If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.
+Added: We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.
+Added: The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases.
+Added: The Company does not recognize leases with terms of twelve months or less on the balance sheet.
+Added: Options to extend or terminate a lease are not included in the Company’s initial lease term assessment, unless there is reasonable certainty that the Company will exercise any such option.
+Added: Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (“ASC”) 842.
+Added: For operating leases, right-of-use assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term.
+Added: In determining the net present value of lease payments, the Company uses an estimated rate of interest that they would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.
+Added: The operating lease right-of-use asset also includes any lease payments made and excludes any lease incentives.
+Added: Lease expense is recognized on a straight-line basis over the expected lease term.
+Added: The Company’s prior lease for its corporate headquarters located at 140 Intracoastal Pointe Dr.
+Added: expired on August 31, 2023, and there was no right-of-use asset or lease liability recognized for this lease due to its short-term nature.
+Added: In August 2023, the Company entered into a new lease ( “1044 N Lease”) comprising approximately 1,719 square feet of office space located at 1044 N US 1, Jupiter, Florida, commencing September 1, 2023 ( “Commencement Date”) and will expire on August 31, 2026.
+Added: Rent is subject to three percent ( 3 %) annual increases, and the Company is responsible for certain common area maintenance charges and taxes throughout the life of the 1044 N Lease.
+Added: The 1044 N Lease has an initial term of three ( 3 ) years, following the Commencement Date with an option to extend for two ( 2 ) successive one ( 1 ) year terms.
+Added: The options were not included in the lease term used in determining the right-of-use asset or lease liability as the Company did not consider it reasonably certain they would exercise the options.
+Added: For the years ended December 31, 2023 and 2022 , the Company’s total operating lease expense was approximately $ 72,000 and $ 58,000 , respectively.
+Added: As of December 31, 2023 , the Company’s total operating lease liabilities was approximately $ 136,929 , which is presented net of imputed interest of $ 16,770 , and the operating lease right-of-use asset was approximately $ 141,439 .
+Added: There were no operating lease liabilities or operating lease right-of-use assets as of December 31, 2022.
+Added: As of December 31, 2023 , the weighted average remaining lease term was 2.7 years, and the weighted average discount rate was 8.8 %.
Research and Development Costs
−Removed: Research and development (“R&D”) costs are expensed as incurred.
−Removed: R&D costs are related to the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
+Added: Research and development (“R&D”) costs are expensed as incurred.
+Added: R&D costs are related to the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.
Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs.
2 unchanged sentences
Outside contracted services
−Removed: $ 3,707,269  
−Removed: $ 7,607,035  
+Added: $ 2,677,941 $ 3,707,269
Personnel related costs
−Removed: 743,051  
−Removed: 773,823  
+Added: 553,741 743,051
Facilities, overhead and other
−Removed: 51,045  
−Removed: 11,512  
−Removed: $ 4,501,365  
−Removed: $ 8,392,370  
+Added: 65,584 51,045
+Added: $ 3,297,266 $ 4,501,365
Foreign Currency Transaction Gain or Loss
The Company and its foreign subsidiary use the U.S.
−Removed: dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date.
+Added: dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date.
Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.
3 unchanged sentences
Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
−Removed: Level 1 –
−Removed: Quoted prices in active markets for identical assets or liabilities.
−Removed: Level 2 –
−Removed: Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
−Removed: Level 3 –
−Removed: Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
−Removed: The Company’s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits.
−Removed: The carrying amount of these financial instruments, except for investment in debt securities, approximates fair value due to the short-term maturities of these instruments.
−Removed: The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third -party broker service for disclosure purposes.
−Removed: Non-Marketable Investments
−Removed: The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do not have a readily determinable fair value.
−Removed: Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example.
−Removed: On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes.
−Removed: If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which may include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others.
−Removed: Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company’s securities.
−Removed: In addition, such investments are inherently risky in that such companies are typically at an early stage of development, may have no or limited revenues, may not be or may never become profitable, may not be able to secure additional funding or their technologies, services or products may not be successfully developed or introduced into the market.
−Removed: On January 18, 2023, the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC (the “Alphazyme Sale Agreement”).
−Removed: After taking into account the adjustments for the transaction and legal expenses, payments to the Company were approximately US$1.27 million in connection with the sale.
−Removed: See Note 8 Subsequent Events for details.
−Removed: For the year ended December 31, 2021, the Company recorded a gain from the sale of its investment in BDI in other income in the amount of approximately $ 1.6  million, net of transaction and legal expenses. 
−Removed: The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, “Income Taxes”.
+Added: Level 1 – Quoted prices in active markets for identical assets or liabilities.
+Added: Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
+Added: Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
+Added: The Company’s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits.
+Added: The carrying amount of these financial instruments, except for investment in debt securities, approximates fair value due to the short-term maturities of these instruments.
+Added: The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third -party broker service for disclosure purposes.
+Added: The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, “Income Taxes”.
Under this method, income tax expense /(benefit) is recognized for:
−Removed: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns.
+Added: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
1 unchanged sentence
A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.
−Removed: In determining taxable income for the Company’s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate.
+Added: In determining taxable income for the Company’s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate.
This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense.
−Removed: In evaluating the Company’s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income.
+Added: In evaluating the Company’s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income.
Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.
−Removed: The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company’s financial statements.
+Added: The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company’s financial statements.
ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return.
For those benefits to be recognized, a tax position must be more-likely-than- not to be sustained upon examination by taxing authorities.
−Removed: Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.”
−Removed: A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740.
+Added: Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740.
+Added: For the year ended December 31, 2023 , other income of approximately $ 1,018,000 was related to the sale of the equity interest in Alphazyme, LLC.
+Added: For the year ended December 31, 2022, other income of $ 250,000 was related to a settlement payment we received from the termination of term sheet of a proposed license and collaboration.
Comprehensive Income (Loss)
−Removed: Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’
−Removed: equity but are excluded from net income (loss) under U.S.
+Added: Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under U.S.
The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.
Stock-Based Compensation
−Removed: We recognize all share-based payments to employees, consultants, and our Board of Directors (the “Board”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments.
+Added: We recognize all share-based payments to employees, consultants, and our Board of Directors (the “Board”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments.
Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.
3 unchanged sentences
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period.
−Removed: Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock, restricted stock units and convertible debt, were exercised and converted into common stock, calculated by applying the treasury stock method.
−Removed: For the years ended December 31, 2022 and 2021 , the effect of the potential exercise of options to purchase 
−Removed: 5,031,097  and 4,774,215  shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.
−Removed: Recently Accounting Pronouncements
−Removed: June 2016, 
−Removed: the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 
−Removed: 2016 - 13,  
−Removed: Financial Instruments - Credit Losses (Topic  
−Removed: Measurement of Credit Losses on Financial Instruments , which modifies the measurement of expected credit losses of certain financial instruments.
−Removed: 2016 - 13  will be effective for the Company beginning in the 
−Removed: first  quarter of 
−Removed:  The Company does 
−Removed: not  expect ASU 
−Removed: 2016 - 13  to have a material impact on our consolidated financial positions, results of operations, and cash flows.
−Removed: Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.
−Removed:      Cash, Cash Equivalent, and Investments
−Removed: The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents.
−Removed: The following table shows the Company’s cash, available-for-sale securities, and investment securities by major security type as of December 31, 2022 and 2021 :
+Added: Diluted net loss per share adjusts the weighted average number of common stock outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock, restricted stock units and convertible debt, were exercised and converted into common stock, calculated by applying the treasury stock method.
+Added: For the years ended December 31, 2023 and 2022 , the effect of the potential exercise of options to purchase 5,469,247 and 5,031,097 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.
+Added: Recently Adopted Accounting Pronouncements
+Added: In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (the “ASU”) 2016 - 13, Financial Instruments — Credit Losses (Topic 326 ) :
+Added: Measurement of Credit Losses on Financial Instruments .
+Added: which replaces the incurred loss model with a forward-looking expected credit loss (“CECL”) model and requires consideration of a broader range of reasonable and supportable information to estimate expected credit losses.
+Added: ASU 2016 - 13 applies to financial assets, measured at amortized cost, including held-to-maturity debt securities and accounts receivable.
+Added: ASU 2016 - 13 must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to members’ equity in the period of adoption.
+Added: The Company adopted ASU 2016 - 13 and related amendments as of January 1, 2023, and the adoption of the new standard did not have a material impact on the Company’s consolidated financial statements.
+Added: Recent Accounting Pronouncements Not Adopted as of December 31, 2023
+Added: In December 2023, the FASB issued Accounting Standards Update 2023 - 09 – Income Taxes (Topic ASC 740 ) Income Taxes.
+Added: The ASU improves the transparency of income tax disclosures by requiring ( 1 ) consistent categories and greater disaggregation of information in the rate reconciliation and ( 2 ) income taxes paid disaggregated by jurisdiction.
+Added: It also includes certain other amendments to improve the effectiveness of income tax disclosures.
+Added: The amendments in ASU 2023 - 09 will become effective beginning with our 2025 fiscal year.
+Added: Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance.
+Added: We do not expect that this guidance will have a material impact on our financial position and results of operations.
+Added: In November 2023, the FASB issued Accounting Standards Update 2023 - 07 – Segment Reporting (Topic ASC 280 ) Improvements to Reportable Segment Disclosures.
+Added: The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosure about significant segment expenses.
+Added: The enhancements under this update require disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of segment profit or loss, require disclosure of other segment items by reportable segment and a description of the composition of other segment items , require annual disclosures under ASC 280 to be provided in interim periods, clarify use of more than one measure of segment profit or loss by the CODM, require that the title of the CODM be disclosed with an explanation of how the CODM uses the reported measures of segment profit or loss to make decisions, and require that entities with a single reportable segment provide all disclosures required by this update and required under ASC 280.
+Added: ASU 2023 - 07 is effective for public business entities for fiscal years beginning after December 15, 2023, with early adoption permitted.
+Added: We continue to evaluate these changes and do not expect that this guidance will have a material impact on our financial position, results of operations, or financial statement disclosures.
+Added: Cash, Cash Equivalent, and Investments
+Added: The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, net of allowance for credit losses, and its investments in money market funds are classified as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets.
+Added: The following table shows the Company’s cash, available-for-sale securities, and investment securities by major security type as of December 31, 2023 and 2022 :
December 31, 2023
3 unchanged sentences
Cash and Cash Equivalents
−Removed: $ 26,782  
−Removed: $ 26,782  
+Added: $ 25,775 $ — $ — $ 25,775
Money Market Funds
−Removed: 5,767,490  
−Removed: 5,767,490  
−Removed: 5,794,272  
−Removed: 5,794,272  
+Added: 1 6,489,253 — — 6,489,253
+Added: 6,515,028 — — 6,515,028
Short-Term Investment Securities (2)
Corporate Bonds (3)
−Removed: 6,800,062  
−Removed: ( 47,208 )  
−Removed: 6,847,270  
−Removed: $ 12,594,334  
−Removed: $ ( 47,208 )  
−Removed: $ 12,641,542  
+Added: 2 748,105 — ( 185 ) 748,290
+Added: $ 7,263,133 $ — $ ( 185 ) $ 7,263,318
December 31, 2022
3 unchanged sentences
Cash and Cash Equivalents
−Removed: $ 1,377,094  
−Removed: $ 1,377,094  
+Added: $ 26,782 $ — $ — $ 26,782
Money Market Funds
−Removed: 14,371,386  
−Removed: 14,371,386  
−Removed: 15,748,480  
−Removed: 15,748,480  
+Added: 1 5,767,490 — — 5,767,490
+Added: 5,794,272 — — 5,794,272
Short-Term Investment Securities (2)
Corporate Bonds (3)
−Removed: 4,509,285  
−Removed: ( 2,495 )  
−Removed: 4,511,780  
−Removed: $ 20,257,765  
−Removed: $ ( 2,495 )  
−Removed: $ 20,260,260  
+Added: 2 6,800,062 — ( 47,208 ) 6,847,270
+Added: $ 12,594,334 $ — $ ( 47,208 ) $ 12,641,542
( 1 ) Definition of the three -level fair value hierarchy:
3 unchanged sentences
( 2 ) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
−Removed: ( 3 ) For the years ended December 31, 2022 and 2021 , the Company received discounts of $ 6,280  and paid premiums of $ 283,940 to purchase held-to-maturity investment securities, 
−Removed: respectively.
+Added: ( 3 ) For the years ended December 31, 2023 and 2022 , the Company received discounts of $ 39,012 and $ 6,280 to purchase held-to-maturity investment securities, respectively.
The Company considers declines in market value of its investment portfolio to be temporary in nature.
−Removed: The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield.
−Removed: When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis.
+Added: The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield.
+Added: When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis.
As of December 31, 2023 , the Company does not consider any of its investments to be other-than-temporarily impaired.
−Removed:      Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-Held Companies
−Removed: A Global Food Ingredient  
−Removed: On May 10, 2022, the Company entered into a Joint Development Agreement (the “JDA”) with a Global Food Ingredient Company (“GFIC”) to develop and manufacture several animal free ingredient products using the Company’s biotechnologies.
−Removed: Under the terms of the JDA, Dyadic is to develop its proprietary production cell lines for the manufacture of animal free ingredient product candidates.
−Removed: The research collaboration will be fully funded by the GFIC in an amount approximating $ 4.1 million over two years.
−Removed: Dyadic will receive certain defined “Success Fees”
−Removed: (the “Success Fees”), upon researching certain productivity and activity levels and milestones at different stages of the collaboration.
−Removed: Dyadic will also receive a “Commercialization Fee”
−Removed: (the “Commercialization Fee”) of low eight figures upon commercialization, and a royalty payment of low single digits based on commercial sales. 
−Removed: The JDA can be terminated in its entirety along with any sublicense granted, with or without cause by either party, within 90  business days after receipt of written termination notice. 
−Removed: Accounting Treatment  
−Removed: The Company considered the guidance in ASC 
−Removed: 808,  Collaborative Arrangements (ASC 
−Removed: 808 ) and determined the JDA is 
−Removed: not  applicable to such guidance. The Company concluded that GFIC represented a customer and applied relevant guidance from ASC 
−Removed: 606,  Revenue from Contracts with Customers (ASC 
−Removed: 606 ) to evaluate the appropriate accounting for the JDA. 
−Removed: The Company identified the following promises under the JDA:
−Removed: ( 1 ) to provide agreed-upon research and development services with GFIC’s proteins;
−Removed: ( 2 ) to nominate a project manager and two additional steering committee members to meet at least quarterly to review the project’s status;
−Removed: ( 3 ) to grant a R&D license in consideration of GFIC’s payment of Service Fees and its other project obligations;
−Removed: and ( 4 ) to grant a commercial license in consideration of and subject to GFIC’s payment of the commercialization fee and royalties. 
−Removed: The Company concluded that, while participation on the joint steering committee was capable of being distinct from other promises, such participation is considered to be part of the research and development services and does not constitute the transfer of a good or service within the context of the JDA. Additionally, the Company concluded that the promise to grant a commercial license is a contingent promise based upon the success of the research project which is outside the control of both the Company and the GFIC, and therefore, it should be accounted for in the same way as a customer option.
−Removed: The Company further concluded that the contingent promise to grant a commercial license is not considered a material right and does not give rise to a separate performance obligation. 
−Removed: Based on management’s assessment, the Company concluded the agreed-upon research and development services and the R&D license under the R&D plan should be combined and accounted for as one single performance obligation in consideration of the service fees.
−Removed: Accordingly, the Company recorded the service fees as research and development revenue using the cost-based input method in accordance with the Company’s policy (Note 
−Removed: Under the JDA, the Company is also eligible to receive Success Fees upon certain milestones, a Commercialization Fee upon commercialization, and future sales-based royalty payments.
−Removed: The Success Fees are considered constrained variable considerations and excluded from the transaction price at inception.
−Removed: The Company will re-evaluate the Success Fees and estimate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.
−Removed: The Company will 
−Removed: not  recognize revenue related to the Commercialization Fee and sales-based royalty until the associated event occurs.
−Removed: For the year ended December 31, 2022 , the Company recorded research and development revenues of approximately $ 790,000  in connection with the JDA.
+Added: Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies
+Added: On September 18, 2023, Dyadic International (USA) Inc., a subsidiary of the Company, signed a Development and Exclusive License Agreement (the “Inzymes Agreement”) with Inzymes ApS (“Inzymes”), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic’s proprietary Dapibus™ platform.
+Added: Under the terms of the Inzymes Agreement, a research collaboration to develop a basket of dairy enzymes will be fully funded by Inzymes with an upfront payment of $ 0.6 million and an additional payment payable upon the first commercial sale of product.
+Added: Dyadic will also be eligible to receive success fees upon the achievement of certain target yields, milestone payments upon the first commercial sale of each product and royalties.
+Added: In October 2023, the Company received the upfront payment of $ 0.6 million in accordance with the terms of the Inzymes Agreement.
+Added: The payment consisted of funding for specified product research and development efforts and right of first refusal for certain product candidates.
+Added: For the year ended December 31, 2023 , the Company recorded research and development revenues of approximately $ 110,000 , in connection with the Inzymes Agreement.
+Added: A Global Food Ingredient Company
+Added: On May 10, 2022, the Company entered into a Joint Development Agreement (the “JDA”) with a Global Food Ingredient Company (“GFIC”) to develop and manufacture several animal free ingredient products using the Company’s biotechnologies.
+Added: Under the initial terms of the JDA, Dyadic was to develop its proprietary production cell lines for the manufacture of animal free ingredient product candid ates.
+Added: As of December 31, 2023, th e GFIC has completed its one -year funding commitment for the initial phase of research collaboration in an amount approximatin g $1.35 million, and, pu rsuant to the GFIC’s rights under the JDA, the Company and the GFIC are conferring to decide whether or not, and if it is possible, to move forward to the next phase of the project.
+Added: The Company is also considering other funding sources to continue the project.
+Added: For the years ended December 31, 2023 and 2022 , the Company recorded research and development revenues, including milestone payments, of approximate ly $ 631,000 and $ 790,000 , respectively, in c onnection with the JDA.
On February 10, 2022, the Company entered into an exclusive sub-license agreement with Abic Biological Laboratories Ltd.
−Removed: (“Abic”), an affiliate of Phibro Animal Health Corporation (“Phibro”) to provide services for a targeted disease (the “Phibro/Abic Agreement”).
+Added: (“Abic”), an affiliate of Phibro Animal Health Corporation (“Phibro”) to provide services for a targeted disease (the “Phibro/Abic Agreement”).
The Phibro/Abic Agreement was an addendum to the initially non-exclusive sub-license agreement the Company signed with Phibro on July 1, 2020.
According to the Phibro/Abic Agreement, the Company received an exclusivity payment in April 2022.
−Removed: In July 2022, the Company expanded the license agreement to include an additional research project to develop another animal vaccine for livestock. 
−Removed: Phibro/Abic may terminate the Phibro/Abic Agreement in its entirety, or any sublicense granted, in each case with or without cause at any time upon 90 days’ prior written notice to Dyadic. 
−Removed: Accounting Treatment
−Removed: The Company considered the guidance in ASC 808, Collaborative Arrangements (ASC 808 ) and determined the Phibro Agreement is not applicable to such guidance. The Company concluded that Phibro/Abic represented a customer and applied relevant guidance from ASC 606, Revenue from Contracts with Customers (ASC 
−Removed: 606 ) to evaluate the appropriate accounting for the Phibro/Abic Agreement. 
−Removed: The Company identified the following obligations under the Phibro/Abic Agreement:
−Removed: ( 1 ) an exclusive right to utilize the C1 -cell protein production platform for certain disease;
−Removed: ( 2 ) our obligation to provide agreed-upon research and development services;
−Removed: ( 3 ) research report to be provided to Phibro/Abic based on the requirements of the agreement.
−Removed: Based on management’s assessment, the Company concluded two performance obligations should be accounted for separately:
−Removed: ( 1 ) the agreed-upon research and development services, and ( 2 ) the right to exclusively access and use C1 -cell protein production platform for certain disease.
−Removed: Accordingly, the Company records the R&D services as research and development revenue using the cost-based input method in accordance with the Company’s policy (Note 1 ). 
−Removed: Under the Phibro/Abic Agreement, the Company has received an exclusivity payment in April 2022 and is elgible to receive certain milestone payment upon regulatory approval, and future sales-based royalty payments.
+Added: Since then, the Company has expanded the license agreement to include additional research projects to develop animal vaccines for livestock.
+Added: Under the Phibro/Abic Agreement, the Company has received an exclusivity payment in April 2022 and is eligible to receive certain milestone payment upon regulatory approval, and future sales-based royalty payments.
The milestone payment is considered constrained variable consideration and excluded from the transaction price at inception .
The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.
−Removed: The Company will not recognize revenue related to sales-based royalty until the associated event occurs.
−Removed: On December 16, 2021, the Company entered into a Research, License, and Collaboration Agreement (the “Janssen Agreement”) for the manufacture of therapeutic protein candidates using its C1 -cell protein production platform with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”).
−Removed: Pursuant to the terms of the Janssen Agreement:
−Removed: (i) Janssen will pay Dyadic an upfront payment of $ 500,000 for a non-exclusive license to utilize the C1 -cell protein production platform to develop C1 production cell lines for the manufacturing of Janssen’s therapeutic protein candidates against several biologic targets, (ii) Janssen will provide R&D funding up to €1.6 million to develop and assess C1 production cell lines for its product candidates, (iii) Janssen will have an option to pay a mid- seven figure payment for an exclusive license from Dyadic to use the C1 -cell protein production platform for the manufacturing of therapeutic proteins directed to one specific target, and upon exercise, Janssen would have the right to add additional non-exclusive targets to the collaboration and Dyadic would complete the technology transfer of the C1 -cell protein production platform, fully enabling Janssen to internally develop C1 cell lines against licensed targets, and upon successful completion of the technology transfer, Dyadic is eligible to receive a milestone payment in the low seven figures, (iv) for each product candidate, Dyadic could receive development and regulatory milestones in the mid- seven figures, and (v) Dyadic could receive aggregate commercial milestone payments in the low nine figures per product, subject to a limit on the number of such products, with the amount depending on the cumulative amount of active pharmaceutical ingredient produced by Janssen for each product manufactured with Dyadic’s C1 -cell protein production platform.
−Removed: Janssen may terminate the Janssen Agreement in its entirety, or on a country-by-country or other jurisdiction-by-other jurisdiction basis, for any or no reason, upon 90 days’
−Removed: prior written notice to Dyadic.
−Removed: Accounting Treatment
−Removed: The Company applied ASC 808, Collaborative Arrangements (ASC 808 ) and determined the Janssen Agreement is not applicable to such guidance. The Company concluded that Janssen represented a customer and applied relevant guidance from ASC 606, Revenue from Contracts with Customers (ASC 
−Removed: 606 ) to evaluate the appropriate accounting for the Janssen Agreement. 
−Removed: The Company identified the following promises under the Janssen Agreement:
−Removed: ( 1 ) A right to access the C1 -cell protein production platform;
−Removed: ( 2 ) our obligation to provide agreed upon research and development services under the R&D Funding;
−Removed: ( 3 ) participation in the joint steering committee;
−Removed: ( 4 ) the reservation of targets;
−Removed: ( 5 ) the grant of option to obtain a research license of intellectual property and know-how rights of its C1 -cell protein production platform to produce target proteins;
−Removed: ( 6 ) our obligation to complete tech transfer activities upon the exercise of a research license;
−Removed: and ( 7 ) the options to obtain a commercial license and an exclusive license on specific targets.
−Removed: The Company concluded that the research and development services under the R&D Funding represents a separate unit of account, because it is a prerequisite to the license agreement and a third -party contract research organization will be used to conduct the research.
−Removed: The Company also concluded that, while participation on the joint steering committee was capable of being distinct, participation is part of the research and development services and does not constitute the transfer of a good or service to Janssen within the context of the contract.
−Removed: Other promises including the reservation of targets and tech transfer are not capable of being distinct from the licenses within the context of the contract and should therefore not be treated as a separate performance obligation.
−Removed: Additionally, at contract inception, the Company evaluated Janssen’s options for a research license, commercial license and to exercise exclusive rights on certain targets in order to determine whether these options to purchase additional license rights at their standalone selling prices provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer.
−Removed: The Company concluded that these options in the Janssen Agreement are not material rights and do not give rise to a separate performance obligation.
−Removed: Instead, these options are deemed as marketing offers, and additional option fee payments are recognized or being recognized as revenue when Janssen exercises the option.
−Removed: The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.
−Removed: Based on management’s assessment, the Company concluded two performance obligations should be accounted for separately:
−Removed: ( 1 ) the agreed-upon research and development services, and ( 2 ) the right to access C1 -cell protein production platform under the research plan.
−Removed: Accordingly, the Company will record the €1.6 million of R&D Funding as research and development revenue using the cost-based input method in accordance with the Company’s policy (See Note 1 ).
−Removed: As noted above, the Company received a non-refundable upfront payment of $ 0.5  million to reserve the initial protein targets until Janssen decides to exercise an option to license in the future, which represents a right to access the C1 -cell protein production platform prior to using it.
−Removed: The Company will recognize the upfront payment of $ 0.5 million over the target reservation period, during which Janssen can obtain a research and/or commercial license and/or an exclusive license on specific targets, or recognize in full when the contract is terminated. 
−Removed: The Company also excluded option exercise fees and future milestone payments that the Company was eligible to receive under the Janssen Agreement, from the initial transaction price. The Company will not recognize revenue related to option exercise payments and future milestone payments until the associated event occurs, or relevant thresholds are met.
−Removed: The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.
−Removed: December 31, 2022 ,  
−Removed: the deferred license revenue, current and non-current portion were approximately $ 176,000  and $ 176,000 , respectively. For the years ended December 31, 2022  and 2021, the Company recorded research and development revenues of $ 539,000 and $0, respectively, in connection with the Janssen Agreement. As of 
−Removed: December 31, 2022 and 2021 , approximately $ 121,000  and $ 0 of accounts receivable were related to the Janssen Agreement, respectively. 
−Removed: IDBiologics, Inc. 
−Removed: On July 8, 2020, the Company entered into a Common Stock Purchase Agreement (the “IDBiologics Agreement”) with IDBiologics, Inc (“IDBiologics”).
−Removed: IDBiologics is a private biotechnology company focused on the development of human monoclonal antibodies for the treatment and prevention of serious infectious diseases.
−Removed: The Company was founded in 2017 and seeded by Vanderbilt University Medical Center in response to the repeated threats of epidemics around the world including Ebola in West Africa and Zika in the Americas.
−Removed: IDBiologics is developing a portfolio of monoclonal antibodies against SARS-CoV- 2, influenza and Zika viruses.
−Removed: Pursuant to the term of the IDBiologics Agreement, on July 8, 2021, 
−Removed: Dyadic received 129,661 shares of IDBiologics’
−Removed: common stock, which represent 0.37 % of IDBiologics’
−Removed: outstanding equity, in exchange of a feasibility study performed by Dyadic.
−Removed: Dyadic provided services including the use of Dyadic’s C1 -cell technology to express a SARS-CoV- 2 monoclonal antibody which IDBiologics licensed from the Vanderbilt Vaccine Center.
−Removed: The Company determined not to record the basis for its equity interest in IDBiologics because the fair value amount of the service provided is considered immaterial.
−Removed: The Company evaluated the nature of its equity interest in IDBiologics and determined that IDBiologics is a VIE due to the capital structure of the entity.
−Removed: However, the Company is not the primary beneficiary of IDBiologics as Dyadic does not have the power to control or direct the activities of IDBiologics that most significantly impact the VIE.
−Removed: As a result, the Company does not consolidate its investment in IDBiologics. 
−Removed: On April 25, 2021, the Company entered into a project agreement (the “Project Agreement”) to provide additional research services to IDBiologics.
−Removed: For the years ended December 31, 2022 and 2021 , the Company recorded research and development revenues of approximatel y $ 109,000 and $ 194,000 , respectively, in connection with IDBiologics.
−Removed: December 31, 2022 and 2021 , $ 0 and approximately $ 27,000 of unbilled accounts receivable were related to IDBiologics, respectively. 
−Removed: On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”).
−Removed: Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc.
−Removed: on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprie tary C1 -cell protein production platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.
−Removed: On June 24, 2020, the Company entered into an Amended and Restated Non-Exclusive Sub-License A greement (the “Amended Sub-License Agreement”) with Alphazyme to amend and restate the Alphazyme Sub-License Agreement. Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic’s transfer of its C1 -cell protein production platform, Alphazyme issued 
−Removed: 2.50 % of the Class A shares of Alphazyme to Dyadic, and Dyadic became a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.
−Removed: In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties on net sales, if any, which incorporate Dyadic’s proprietary C1 -cell protein production platform. 
−Removed: On December 1, 2020, an Amended and Restated Limited Liability Company Agreement with Alphazyme (the “Amended Alphazyme LLC Agreement”) was entered into. Under the Amended Alphazyme LLC Agreement, Alphazyme obtained additional capital contribution and Dyadic’s ownership was diluted to 1.99 %.
+Added: The Company will not recognize revenue related to sales-based royalty until the associated event occurs.
+Added: As of December 31, 2023 , there were no events or circumstances that would change the transaction price and no milestone or royalty payments have been recognized.
+Added: On December 16, 2021, the Company entered a Research, License, and Collaboration Agreement (the “Janssen Agreement”) for the manufacture of therapeutic protein candidates using its C1 -cell protein production platform with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”).
+Added: On October 2, 2 023, Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of December 31, 2023.
+Added: For the years ended December 31, 2023 and 2022 , the Company recognized approximately $ 353,000 and $ 176,000 license revenue and research and development revenues of approximat ely $ 520,000 and $ 539,000 , resp ectively, in connection with the Janssen Agreement.
+Added: As of December 31, 2023 and 2022 , approximately $ 145,000 an d $ 121,000 of accounts receivable were related to Janssen, respectively.
+Added: In 2019 the Company entered into a sub-licensing agreement with Alphazyme, LLC (“Alphazyme”) that was subsequently amended (the “Amended Alphazyme LLC Agreement”).
+Added: Under the Amended Alphazyme LLC Agreement, Alphazyme obtained additional capital contribution and Dyadic’s ownership was diluted to 1.99 %.
The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity.
However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE.
−Removed: As a result, the Company does not consolidate its investment in Alphazyme.
−Removed: The Company reports its investment in Alphazyme under the cost method of accounting, given that it does not have the ability to exercise significant influence or control over Alphazyme. 
−Removed: For the year ended December 31, 2020, 
−Removed: the Company recorded a gain of $ 284,709 from 
−Removed: its investment in Alphazyme resulting from a third -party capital contribution obtained by Alphazyme. As of December 31, 2021, the Company does not consider its investment in Alphazyme to be impaired, as there was no event or transaction that would change the value of this investment. 
−Removed: On January 18, 2023, the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC (the “Alphazyme Sale Agreement”).
−Removed: Net proceeds to the Company were approximately $ 1.27 million in connection with the sale. The Company also has the potential to receive additional payments based on the future sales of Alphazyme’s existing products, pursuant to the Alphazyme Sale Agreement.
+Added: As a result, the Company does not consolidate its investment in Alphazyme.
+Added: The Company reports its investment in Alphazyme under the cost method of accounting, given that it does not have the ability to exercise significant influence or control over Alphazyme.
+Added: On January 18, 2023, the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC (the “Alphazyme Sale Agreement”).
+Added: The Company continues to have the potential to receive additional payments based on the future sales of Alphazyme’s existing products, pursuant to the Alphazyme Sale Agreement.
The Amended Sublicense Agreement between Dyadic and Alphazyme, which was previously entered on June 24, 2020, remains in effect.
−Removed: Under the Amended Alphazyme Sub-License Agreement, Dyadic is entitled to potential milestone and royalty payments upon the commercialization of Alphazyme products using Dyadic’s proprietary C1 -cell protein production platform.
−Removed: On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.
−Removed: (“BDI Pharma”), and with VLP The Vaccines Company, S.L.U.
−Removed: (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings”
−Removed: and together with BDI Pharma and VLPbio, “BDI”).
−Removed: The Company paid EUR €1.0  million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1 % equity interest in BDI Holdings and a 3.3 % equity interest in VLPbio.
−Removed: Under the RSA, BDI is obligated to spend a minimum amount of EUR €936,000 over two years for the research and development project. 
−Removed: The Company concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest.
−Removed: Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations.
−Removed: As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results. 
−Removed: The Company performed a valuation analysis of the components of the transaction and concluded that the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $ 1.1 million (EUR €1.0 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and the collaboration payment under the RSA paid by Dyadic were expensed as the related research services were performed by BDI.
−Removed: On July 26, 2021, the Company entered (i) a Sale and Purchase of Shares Agreement under which the Company agreed to sell its 16.1 % equity interest in BDI Holdings, and (ii) a Sale and Purchase of Shares Agreement under which the Company agreed to sell its 3.3 % equity interest in VLPBio (together the “BDI Sale”).
−Removed: In connection with the closing of the BDI Sale, the Company received approximately $ 1.6  m illion, net of transaction and legal expenses in August 2021.
−Removed: The gain generated from the BDI Sale was recorded in other income.
−Removed: In connection with the BDI Sale, the Company also entered into an amendment to the Service Framework Agreement (the “Amended SFA”) with BDI Pharma. Under the Amended SFA, the Company maintains the right to engage in research and development projects at BDI Pharma until June 30, 2025, with the non-compete term extending to June 30, 2030, without any other material terms and conditions changed.
−Removed: For the years ended December 31, 2022 and 2021, there was no research and development revenue or research and development expenses associated with the Amended SFA.
−Removed: Novovet and Luina Bio 
−Removed: On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd.
−Removed: (“Luina Bio”) and Novovet Pty Ltd (“Novovet”).
−Removed: Under the terms of the Luina Bio Sub-License Agreement, the Company granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc.
−Removed: on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 -cell protein production platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.
−Removed: In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20 % equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement (“Shareholders Agreement”) and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 -cell protein production platform.
−Removed: The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders.
−Removed: However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE.
−Removed: As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.
−Removed: To date Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 -cell protein production platform to Novovet.
−Removed: Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20 % equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606.
−Removed: On February 15, 2022, the Company sent a letter to Luina Bio Pty Ltd and Novovet Pty Ltd, indicating its intention to terminate the Luina Bio Sub-License Agreement. 
−Removed: June 29, 2022, 
−Removed: the Company sent a letter to Luina Bio Pty Ltd and Novovet Pty Ltd, to transfer our shares of Novovet Pty Ltd back to Novovet pursuant to the Shareholders Agreement.
−Removed:      Income Taxes
−Removed: For the year ended December 31, 2022 , there was 
−Removed: no provision for income taxes or unrecognized tax benefits recorded.
+Added: Under the Amended Alphazyme Sub-License Agreement, Dyadic is entitled to potential milestone and royalty payments upon the commercialization of Alphazyme products using Dyadic’s proprietary C1 -cell protein production platform.
+Added: For the year ended December 31, 2023, the Company received a total cash payment of approximately $ 1.3 million from the sale of its equity interest in Alphazyme, LLC.
+Added: For the year ended December 31, 2023 , there was no provision for income taxes or unrecognized tax benefits recorded.
The significant components of gain (loss) before income taxes are as follows:
Years Ended December 31,
−Removed: $ ( 9,828,427 )  
$ ( 6,766,409 ) $ ( 9,828,427 )
Foreign operations
−Removed: 93,169  
−Removed: 45,618  
+Added: ( 29,052 ) 93,169
Total loss before provision for income taxes
−Removed: $ ( 9,735,258 )  
$ ( 6,795,461 ) $ ( 9,735,258 )
−Removed: The Company has no current or deferred income tax for the years ended December 31, 2022 and 2021 .
−Removed: The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to permanent differences, state income taxes and a change in the deferred tax valuation allowance.
−Removed: The reconciliation between the statutory tax rate and the Company’s actual effective tax rate is as follows:
+Added: The Company has no current or deferred income tax for the years ended December 31, 2023 and 2022 .
+Added: The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to permanent differences, state income taxes and a change in the deferred tax valuation allowance.
+Added: The reconciliation between the statutory tax rate and the Company’s actual effective tax rate is as follows:
Years Ended December 31,
statutory rate
−Removed: ( 21.00 )%  
+Added: ( 21.00 )% ( 21.00 )%
State taxes, net of federal benefit
−Removed: ( 4.35 )  
+Added: ( 4.19 ) ( 4.35 )
Non-deductible items
2 unchanged sentences
Foreign operations
+Added: ( 0.11 ) 0.24
Change in tax rate
Effective income tax rate
−Removed: The significant components of the Company’s net deferred income tax assets are as follows:
+Added: The significant components of the Company’s net deferred income tax assets are as follows:
+Added: Section 174 - R&D expenses
+Added: $ 1,769,000 $ 1,046,400
Stock option expense
−Removed: $ 1,341,900  
−Removed: $ 947,400  
+Added: 1,419,300 1,341,900
NOL carryforward
−Removed: 11,524,900  
−Removed: 10,509,900  
+Added: 11,620,700 11,524,900
Research and development credits
−Removed: 1,623,100  
−Removed: 1,656,500  
−Removed: Section 174 - R&D expenses
−Removed: 1,046,400  
−Removed: Unrealized gain from investment in Alphazyme
−Removed: ( 78,200 )  
+Added: 1,503,600 1,623,100
+Added: Operating lease liability
+Added: Right-of-use asset
+Added: 134,800 ( 78,200 )
Deferred tax asset, net of deferred tax liabilities
−Removed: 15,458,100  
−Removed: 13,035,600  
+Added: 16,446,300 15,458,100
Valuation allowance
−Removed: ( 15,458,100 )  
( 16,446,300 ) ( 15,458,100 )
4 unchanged sentences
Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
−Removed: Based on Management’s evaluation, the net deferred tax asset, was offset by a full valuation allowance as of December 31, 2022 
−Removed: The Company had net operating loss (“NOL”) carryforwards available as of December 31, 2022, and 2021, in the amount of approximately $ 44.0 million and $ 39.9 million, respectively.
−Removed: Approximately $ 41.1 million of the net operating loss carryforwards will be carried forward indefinitely and will be available to offset 80 % of taxable income.
+Added: Based on Management’s evaluation, the net deferred tax asset, was offset by a full valuation allowance as of December 31, 2023 and 2022.
+Added: The Company had federal and state net operating loss (“NOL”) carryforwards available as of December 31, 2023, and 2022, in the amount of approximately $ 45.9 million and $ 44.0 million, respectively.
+Added: Approximately $ 42.9 million of the federal net operating loss carryforwards will be carried forward indefinitely and will be available to offset 80 % of taxable income.
The remaining amount of the net operating loss carryforwards will expire at varying dates through 2037.
−Removed: The Tax Cuts and Jobs Act eliminated the current year deduction election for research and experimental expenditures.
+Added: In addition, the Company had foreign net operating loss carryforwards available as of December 31, 2023, and 2022, in the amounts of approximately $ 1.4 million and $ 1.4 million.
+Added: These foreign net operating loss carryforwards will begin to expire, if unused, in various amounts between 2025 and 2027.
+Added: The Tax Cuts and Jobs Act eliminated the current year deduction election for research and experimental expenditures.
Instead, a taxpayer must charge such expenditures to a capital account and is allowed to amortize such expenditures ratably over a five -year period (or fifteen -year period for expenditures attributable to foreign research), beginning with the midpoint of the tax year in which such expenditures are paid or incurred.
−Removed:      Commitments and Contingencies
+Added: Commitments and Contingencies
Jupiter Florida Headquarters
−Removed: The Company’s corporate headquarters are located in Jupiter, Florida.
−Removed: The Company occupies approximately 2,000 square feet with a monthly rental rate and common area maintenance charges of approximately $ 4,500 .
−Removed: The lease will expire on September 1, 2023.
−Removed: The Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company. 
+Added: In August 2023, the Company entered into a new lease comprising approximately 1,719 square feet of office space located at 1044 N US 1, Jupiter, Florida, commencing September 1, 2023, and will expire on August 31, 2026.
+Added: The Company occupies this space for an annual rental rate of approximately $ 59,000 .
The Netherlands Office
2 unchanged sentences
The lease expires on January 31, 2025, and thereafter, the Company will reconsider the leased space to a lign with the future operations of the Company.
−Removed: VTT Research Contract Extension
−Removed: On September 12, 2022, the Company extended its research contract (“Amendment”) through December 2023 with VTT Technical Research Centre of Finland Ltd.
−Removed: (“VTT”). Under the terms of this Amendment, Dyadic will pay VTT a total of approximately EUR €1.1 million over 
−Removed: fifteen months to continue developing Dyadic’s C1 -cell protein production platform for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third -party target protein projects. Dyadic retains the right to terminate the Contract with 90 days’
+Added: As of December 31, 2023 , the future minimum annual lease payments under the operating leases are below.
+Added: There are no future minimum annual lease payments after 2026.
Purchase Obligations
−Removed: The following table provides a schedule of commitments related to agreements to purchase certain services in the ordinary course of business, as of December 31, 2022 :
−Removed: $ 2,912,761  
−Removed: 164,794  
−Removed: 40,951  
−Removed: $ 3,118,506  
−Removed: The purchase obligations in the table above are primarily related to our contracts with the Company’s contract research organizations to provide certain research services.
−Removed: The contracts set forth the Company’s minimum purchase requirements that are subject to adjustments based on certain performance conditions.
−Removed: All contracts expire in or prior to 2024.
+Added: Purchase obligations are primarily related to our contracts with the Company’s contract research organizations to provide certain research services.
+Added: The contracts set forth the Company’s minimum purchase requirements that are subject to adjustments based on certain performance conditions.
+Added: The commitments related to agreements to purchase certain services in the ordinary course of business, as of December 31, 2023 is approximately $ 932,000 .
+Added: All current contracts expire in 2024.
+Added: VTT Research Contract Extension
+Added: On January 31, 2024, the Company entered into the Third Amendment to the commission contract concerning VTT Technical Research Centre of Finland Ltd.
+Added: (“VTT”) to develop Dyadic’s C1 fungal expression system for ther apeutic protein production.
+Added: The original contract was entered on June 28, 2019, and subsequently amended by the First Amendment on June 21, 2022 and the Second Amendment on September 9, 2022.
+Added: Under the terms of the Third Amendment, the contract duration is extended to January 31, 2025 and Dyadic will pay VTT approximately a total of EUR €186,000 to continue developing Dyadic’s C1 -cell protein production platform for therapeutic protein production, including C1 host system.
+Added: Dyadic retains the right to terminate the contract with 90 days’ notice.
Legal Proceedings
4 unchanged sentences
Litigation is inherently unpredictable and costly.
−Removed: Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.
−Removed:      Share-Based Compensation
+Added: Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.
+Added: Share-Based Compensation
Description of Equity Plans
−Removed: The 2021 Equity Incentive Award Plan (the “2021 Plan”) was adopted by the Company's Board of Directors on April 9, 2021, and approved by the Company’s Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2021.
−Removed: The 2021 Plan serves as a successor to the Company’s 2011 Equity Incentive Plan (the “2011 Plan”).
−Removed: Since the effective date of the 2021 Plan, all equity awards were made from the 2021 Plan, and no additional awards will be granted under the 2011 Plan.
−Removed: The 2021 Plan is reserved for issuance of a variety of share-based compensation awards, including stock options, restricted stock awards, restricted stock unit awards, performance award, dividend equivalents award, deferred stock awards, stock payment awards and stock appreciation rights.
−Removed: The 2021 Plan increased the number of shares available for grant by 
−Removed: 3,000,000  in addition to the number of shares remaining available for the grant of new awards under the 2011  Plan as of April 16, 2021.
−Removed: As of December 31, 2022 , the Company had 5,031,097  stock options outstanding and an additio nal 
−Removed: 3,672,561 share s of common stock available for grant under the 2021 Plan.
−Removed: As of December 31, 2021 , there were 4,774,215  stock options outstanding and an additional 4,263,386  shares of common stock available for grant under the 2021 Plan.
+Added: The 2021 Equity Incentive Award Plan (the “2021 Plan”) was adopted by the Company's Board of Directors on April 9, 2021, and approved by the Company’s Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2021.
+Added: The 2021 Plan serves as a successor to the Company’s 2011 Equity Incentive Plan (the “2011 Plan”).
+Added: Since the adoption of the 2021 Plan, all equity awards were made from the 2021 Plan and no additional awards will be granted under the 2011 Plan.
+Added: The 2021 Plan provides for the issuance of a variety of share-based compensation awards, including stock options, restricted stock awards, restricted stock unit awards, performance awards, dividend equivalents awards, deferred stock awards, stock payment awards and stock appreciation rights.
+Added: As of April 16, 2021, the 2021 Plan increased the number of shares available for grant by 3,000,000 in addition to the number of shares remaining available for the grant of new awards under the 2011.
+Added: As of December 31, 2023 , the Company had 5,469,247 stock options outstanding and an additio nal 2,773,406 share s of common stock available for grant under the 2021 Plan.
+Added: As of December 31, 2022 , there were 5,031,097 stock options outstanding and an additional 3,672,561 shares of common stock available for grant under the 2021 Plan.
Stock Options
1 unchanged sentence
Vesting is determined by the Board of Directors at the time of grant.
−Removed: The term of any stock option awards under the Company’s 2011 Plan and 2021 Plan is ten years, except for certain options granted to the contractors which are either one or three years.
+Added: The term of any stock option awards under the Company’s 2011 Plan and 2021 Plan is ten years, except for certain options granted to the contractors which are either one or three years.
The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards.
6 unchanged sentences
Expected stock price volatility.
−Removed: The expected stock price volatility was calculated based on the Company’s own volatility.
−Removed: The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatilities. 
+Added: The expected stock price volatility was calculated based on the Company’s own volatility.
+Added: The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatilities.
Expected life of option.
The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior.
−Removed: The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., 5 or 10 years) and certain contractors (i.e., 1  or 3 years).
−Removed: The assumptions used in the Black-Scholes option pricing model for stock options granted for the years ended 
−Removed: December 31, 2022 and 2021  are as follows:
+Added: The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., 5 or 10 years) and certain contract ors (i.e., 1 or 3 years).
+Added: The assumptions used in the Black-Scholes option pricing model for stock options granted for the years ended December 31, 2023 and 2022 are as follows:
Years Ended December 31,
1 unchanged sentence
1.40 % - 3.24 %
−Removed: 0.05 % - 1.24 %
Expected dividend yield
3 unchanged sentences
Expected life of options (in years)
−Removed: The following table summarizes the combined stock option activity under the Company’s Equity Compensation Plans:
+Added: The following table summarizes the combined stock option activity under the Company’s Equity Compensation Plans:
Exercise Price
Outstanding at December 31, 2021
−Removed: 4,638,390  
−Removed: $ 2.44  
−Removed: $ 13,701,610  
−Removed: 870,825  
−Removed: ( 735,000 )  
+Added: 4,774,215 $ 3.04 6.14 $ 8,413,444
+Added: ( 333,943 ) 1.63
+Added: ( 200,000 ) 5.47
+Added: ( 75,000 ) 4.81
Outstanding at December 31, 2022
−Removed: 4,774,215  
−Removed: $ 3.04  
−Removed: $ 8,413,444  
−Removed: 865,825  
−Removed: Exercised (2)
−Removed: ( 333,943 )  
−Removed: ( 200,000 )  
−Removed: ( 75,000 )  
+Added: 5,031,097 $ 3.25 5.75 $ 13,000
+Added: ( 351,520 ) 1.71
+Added: ( 15,680 ) 3.50
Outstanding at December 31, 2023
−Removed: 5,031,097  
−Removed: $ 3.25  
−Removed: $ 13,000  
+Added: 5,469,247 $ 3.08 5.66 $ 322,738
Exercisable at December 31, 2023
−Removed: 3,655,280  
−Removed: $ 2.80  
−Removed: $ 13,000  
+Added: 4,160,298 $ 3.15 4.81 $ 161,427
( 1 ) Represents the following stock options granted:
−Removed: Annual share-based compensation awards on January 3, 
−Removed: 2022, including:
−Removed: (a) 325,000 stock options with an exercise price of $ 4.81 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 75,000 performance-based stock option to a key personnel with an exercise price of 
−Removed: $4.81 per share, vesting upon the achievement of specified performance conditions, (c) 277,500 stock options with an exercise price of $4.81 per share granted to members of the Board of Directors, vesting upon one year anniversary, (d) 23,325 stock options with an exercise price of $ 4.81  per share granted to employees, vesting annually in equal installments over four years and (e) 15,000 stock options with an exercise price of $ 4.81  per share granted to a consultant, vesting upon one year anniversary.
−Removed: One-time award on June 10, 2022, 150,000 stock options with an exercise price of $ 2.60 per share granted to the Board of Directors, vesting in one year from the grant date as a result of a reduction in director cash compensation.
−Removed: ( 2 ) Represents the following stock options exercised:
−Removed: 150,000 stock options exercised at $ 1.87 , 40,000 stock options exercised at $ 1.63 , 8,943  stock options exercised at $ 1.57 , and 50,000 stock options exercised at $ 1.44 , 50,000  stock options exercised at $ 1.39 , and 35,000 stock options exercised at $ 1.21 .
+Added: Annual share-based compensation awards on January 3, 2023, including:
+Added: (a) 406,250 stock options with an exercise price of $ 1.38 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 262,500 stock options with an exercise price of $ 1.38 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 24,100 stock options with an exercise price of $ 1.38 per share granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options with an exercise price of $ 1.38 per share granted to a consultant, vesting upon one year anniversary.
+Added: • Throughout the year the following stock options were granted:
+Added: (a) on May 30, 2023, 37,500 stock options with an exercise price of $ 2.23 per share granted to a consultant, vesting over two months from the grant date, (b) on September 15, 2023, 55,000 stock options with an exercise price of $ 1.75 per share granted to a consultant, vesting over a year and half from the grant date, and (c) on October 23, 2023, 5,000 stock options with an exercise price of $ 1.66 per share granted to an employee vesting annually in equal installments over four years.
( 2 ) Represents the following stock options expired:
−Removed: 30,000 stock options with exercise price of $ 6.87 , 90,000 stock options with exercise price of $ 5.27 , 80,000 stock option with exercise price of $ 5.16 .
−Removed: ( 4 ) Represents the cancellation of performance-based stock options granted to the Company’s former Managing Director of Business Development and Licensing, who separated from the Company on April 22, 2022.
−Removed: The weighted average grant-date fair market value of stock options granted for the years ended December 31, 2022 and 2021 was $ 2.49 and $ 2.49 , respectively, bas ed on the Black-Scholes option pricing model.
−Removed: The intrinsic value of options exercised for the years ended December 31, 2022 and 2021 was $ 365,000  and $ 1,730,000 , respectively.
−Removed: As of December 31, 2022 and 2021 , total unrecognized compensation cost related to non-vested stock options granted under the Company’s equity compensation plans was $ 919,000  and $ 857,000 , respectively, which is expected to be recognized over a weighted average period of 2.76  years and 3.07  years, respectively.
−Removed: The Company will adjust unrecognized compensation cost for actual forfeitures as they occur.
+Added: 27 0,000 stock options with an exercise price of $ 1.39 per share granted to executive, (b) 25,000 stock options with an exercise price of $ 3.99 per share granted to a consultant, (c) 25,000 stock options with an exercise price of $ 1.75 per share granted to a member of the Board of Directors, (d) 31,520 stock options with an exercise price ranging between $ 1.39 and $ 5.27 per share granted to a former employee.
+Added: ( 3 ) Represents the cancellation of unvested portion of the stock options granted previously to a former employee with exercise price ranging between $ 1.39 to $ 5.27 .
+Added: The weighted average grant-date fair market value of stock options granted for the years ended December 31, 2023 and 2022 was $ 0.81 and $ 2.49 , respectively, based on the Black-Scholes option pricing model.
+Added: The intrinsic value of options exercised for the years ended December 31, 2023 and 2022 was $ 0 and $ 365,000 , respectively.
+Added: As of December 31, 2023 and 2022 , total unrecognized compensation cost related to non-vested stock options granted under the Company’s equity compensation plans was $ 559,121 and $ 919,000 , respectively, which is expected to be recognized over a weighted average period of 2.68 years and 2.76 years, respectively.
+Added: The Company adjusts unrecognized compensation cost for actual forfeitures as they occur.
+Added: Restricted Stock Units
+Added: Restricted stock units (the “RSUs”) are granted subject to certain restrictions.
+Added: Vesting conditions are determined at the discretion of the Board of Directors.
+Added: The fair market value of RSUs is generally determined based on the closing market price of the stock on the grant date.
+Added: The following table summarizes the restricted stock award activity during the year ended December 31, 2023 :
+Added: Weighted-Average
+Added: Outstanding at December 31, 2022
+Added: ( 247,961 ) 1.38
+Added: Outstanding at December 31, 2023
+Added: 213,044 $ 1.38
+Added: ( 1 ) On January 3, 2023, the Company granted 247,961 RSUs with immediate vesting, to executives and key personnel in lieu of cash bonuses earned for the year ended 2022.
+Added: The Company also granted 163,044 RSUs, vesting upon one year anniversary of the grant, to the Board of Directors as a result of the Board agreeing to a reduction in director cash compensation for 2023.
+Added: On December 6, 2023, the Company granted 50,000 RSUs to a consultant, vesting at the end of the service period.
Compensation Expenses
−Removed: We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows.
+Added: We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows.
Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.
1 unchanged sentence
For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.
−Removed: There was no performance-based award recognized during the years ended 
−Removed: December 31, 2022 and 2021 .
+Added: There was no performance-based award recognized during the years ended December 31, 2023 and 2022 .
Total non-cash stock option compensation expense was allocated among the following expense categories:
1 unchanged sentence
General and administrative
−Removed: $ 1,661,025  
−Removed: $ 1,571,328  
+Added: $ 1,201,027 $ 1,661,025
Research and development
−Removed: 227,919  
−Removed: 212,774  
−Removed: $ 1,888,944  
−Removed: $ 1,784,102  
−Removed:      Shareholders’
+Added: 43,094 227,919
+Added: $ 1,244,121 $ 1,888,944
+Added: The following table summarizes the Company’s non-cash share-based compensation expenses:
+Added: Years Ended December 31,
+Added: Share based compensation expense- stock options
+Added: $ 1,004,054 $ 1,888,944
+Added: Share based compensation expense- restricted stock units
+Added: $ 1,244,121 $ 1,888,944
+Added: Shareholders’ Equity
Issuances of Common Stock
−Removed: For the years ended December 31, 2022 and 2021  there were 333,943  and 735,000  shares of the Company's common stock issued, as a result of the exercise of stock options, with a weighted average issue price per share of $ 1.63  and $ 1.67 , respectively.
+Added: For the year ended December 31, 2023 , there were 247,961 shares of the Company’s common stock issued resulting from the vesting of restricted stock units with a weighted average issue price of $ 1.38 per share.
+Added: For the year ended December 31, 2022, there were 333,943 shares of the Company’s common stock issued resulting from the exercise of stock options, with a weighted average issue price of $ 1.63 per share.
Treasury Stock
−Removed: As of December 31, 2022 , and 2021 , there were 12,253,502  shares of common stock held in treasury, at a cost of approximately $ 18.9 million, representing the purchase price on the date the shares were surrendered to the Company.
−Removed: Open Market Sale Agreement℠
−Removed: On August 13, 2020, we entered into an Open Market Sale Agreement℠
−Removed: with Jefferies LLC (“Jefferies”), with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $ 0.001  per share, having an aggregate offering price of up to $ 50.0  million through Jefferies as our sales agent or principal.
−Removed: We have not and are not obligated to sell any shares under the sale agreement.
−Removed: Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations.
−Removed: Under the sale agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an “at the market offering”
−Removed: as defined in Rule 415 (a)( 4 ) under the Securities Act of 1933, as amended.
−Removed: We will pay Jefferies a commission equal to 
−Removed: 3.0 % of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights.
−Removed: In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $ 50,000 , in addition to certain ongoing disbursements of Jefferies’
−Removed: counsel, if required.
−Removed: The sale agreement will terminate upon the sale of all $ 50.0  million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.
−Removed: The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S- 3 filed with the SEC on August 13, 2020 and declared effective by the SEC on August 25, 2020 and the accompanying Prospectus, as supplemented by a Prospectus Supplement.
−Removed: As of the date of this filing, there have been no sales made under the Open Market Sale Agreement℠, and we have no immediate plans to sell any securities under this program to fund our near-term business plan.
−Removed:      Subsequent Events
+Added: As of December 31, 2023 , and 2022 , there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $ 18.9 million, representing the purchase price on the date the shares were surrendered to the Company.
+Added: Subsequent Events
For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March 28, 2024 , the date the consolidated financial statements were available to be issued.
−Removed: Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.
−Removed: Stock Option Grant
+Added: Except for items mentioned in the notes, and as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.
+Added: 2024 Annual Grants
On January 2, 2024, the Company granted an annual stock option award with an exercise price of $ 1.59 , including:
−Removed: (a) 406,250 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 262,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 24,100  stock options granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options granted to a consultant, vesting upon one year anniversary. 
−Removed: On January 3, 2023, the Company granted 247,961 restricted stock units (“RSUs”) vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended 2022.
−Removed: The Company also granted 163,044 RSUs, vesting upon 
−Removed: one year anniversary, to the Board of Directors as a result of reduction in director cash compensation of 2023.
−Removed:  The grant of these RSUs has been approved by the Compensation Committee of the Board of Directors in November 2022.
−Removed: Sale of Equity Interest in Alphazyme 
−Removed: On January 18, 2023, the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC.
−Removed: After taking into account the adjustments for the transaction and legal expenses, payments to the Company were approximately $ 1.27 million in connection with the sale. The Company also has the potential to receive additional payments based on the future sales of Alphazyme’s existing products, pursuant to the Alphazyme Sale Agreement.
−Removed: The Amended and Restated Non-Exclusive Sublicense Agreement between Dyadic and Alphazyme, which was previously entered on June 24, 2020, remains in effect, under which, Dyadic is entitled to potential milestone and royalty payments upon the commercialization of Alphazyme products using Dyadic’s proprietary C1 -cell protein production platform.
+Added: (a) 387,500 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 352,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 17,600 stock options granted to employees, vesting annually in equal installments over four years, and (d) 15,000 stock options granted to a consultant, vesting upon one year anniversary.
+Added: On January 2, 2024, the Company grant ed 141,510 restricted stock units , vesting upon one year anniversary, to the Board of Directors as a result of reduction in director cash compensation of 2024.
+Added: The grant of these RSUs has been approved by the Compensation Committee of the Board of Directors in December 2023.
+Added: On March 11, 2024, the Compensation Committee of the Board of Directors approved and granted an aggregate of 212,709 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended December 31, 2023.
+Added: Senior Secured Convertible Promissory Notes
+Added: On March 8, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued 8.0 % Senior Secured Convertible Promissory Notes due March 8, 2027 in an aggregate principal amount of $ 6.0 million (the “Convertible Notes”).
+Added: The purchasers of the Convertible Notes include immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust U/A/D February 28, 1996, an existing holder of more than 5% of our outstanding common stock, (collectively, the “Purchasers”).
+Added: The Convertible Notes were sold in a private placement in reliance on the exemption from registration provided by Section 4 (a)( 2 ) of the Securities Act of 1933, as amended.
+Added: The net proceeds from the sale of the Convertible Notes, after deducting offering expenses, will be approximately $ 5,850,000 .
+Added: The Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes.
+Added: The Convertible Notes will be senior, secured obligations of the Company and its affiliates, and interest will be payable quarterly in cash on the principal amount equal to 8 % per annum, and guaranteed by Dyadic International (USA), Inc.
+Added: under a subsidiary guarantee for the benefit of the holders of the Convertible Notes (each such holder, a “Holder”).
+Added: The Convertible Notes will mature on March 8, 2027 , unless earlier converted or redeemed in accordance with the terms of the Convertible Notes.
+Added: The Convertible Notes are secured by a first priority lien on substantially all assets of the Company and its subsidiary, Dyadic International (USA), Inc., pursuant to the Security Agreement (as defined below).
+Added: The Convertible Notes are convertible into shares of the Company’s common stock, in whole or in part, at the option of the Holders at any time, based on an initial conversion price of $ 1.79 per share of common stock, subject to adjustment in certain circumstances;
+Added: provided that the Company shall not effect any Conversion of a Note and the Holder thereof shall not have any right to convert any portion of such Note to the extent that, after giving effect to such conversion, such Holder would beneficially own shares of the company in excess of the limits provided in the applicable Convertible Notes;
+Added: provided further that the Company shall not issue any common stock pursuant to the terms of the Convertible Notes if such issuance would exceed 19.99% of the Company’s issued and outstanding Common Stock on date of the Purchase Agreement or otherwise exceed the aggregate number of shares of Common Stock which the Company may issue without breaching the Company’s obligations under the rules or regulations of Nasdaq.
+Added: The Holders may require the Company to redeem all or any part of the Convertible Notes on a redemption date falling on any of the 18, 21, 24, 27, 30, and 33 -month anniversaries of the original issue date of the Convertible Notes (any such date, a “Redemption Date”) upon not less than 60 calendar days written notice prior to the applicable Redemption Date.
+Added: The Company may also elect to redeem all or any part of the Convertible Notes on a Redemption Date upon not less than 60 calendar days written notice prior to the applicable Redemption Date.
+Added: The Convertible Notes contain customary terms and covenants and customary events of default ("Events of Default”).
+Added: Upon the occurrence of any Event of Default, at the Holder’s election, the outstanding principal amount of the applicable Convertible Notes, plus accrued but unpaid interest, liquidated damages, and other amounts owing in respect thereof through the date of acceleration, shall become immediately due and payable.
+Added: After the occurrence of any Event of Default that results in the eventual acceleration of any Note, the interest rate on such Note shall accrue at an interest rate equal to 18 % per annum (with a credit for any “unused” guaranteed interest).
+Added: The Securities Purchase Agreement also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions) and customary representations and warranties of the Company and the Purchasers, indemnification obligations of the Company, termination provisions, and other obligations and rights of the parties.
+Added: The Company also entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company has agreed to register under the Securities Act any common stock of the Company issuable upon conversion of the Convertible Notes.
+Added: The Company also entered into a security agreement (the “Security Agreement”) with the Purchasers, pursuant to which the Company granted the Purchasers a continuing security interest in certain collateral to secure the full and prompt payment, performance and observance of all present and future indebtedness, obligations, liabilities and agreements of any kind of the Company to the Purchasers arising under or in connection with the Convertible Notes.
+Added: Dyadic International (USA), Inc., a subsidiary of the Company (the “Guarantor”) also entered into a subsidiary guarantee (the “Subsidiary Guarantee”) with the Purchasers, pursuant to which the Guarantor has guaranteed to the Purchasers the prompt and complete payment and performance when due of the obligations under the Securities Purchase Agreement.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.